✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
No actionable change — this is a critical letter disputing a mechanistic claim; audiologists should remain aware of tinnitus as a potential drug side effect but should not alter practice based on this correspondence alone.
✦ Why It Matters ✦
Drug-induced tinnitus (ototoxicity-related ringing in the ears) is a significant clinical concern, and rigorous scrutiny of proposed biological mechanisms helps prevent premature adoption of unproven causal explanations.
✦ Key Points ✦
- 01Letter challenges the proposed causal chain linking the mTOR inhibitor everolimus to tinnitus.
- 02Authors argue the mechanistic reasoning in the original paper contains significant logical or evidential gaps.
- 03Published in Drug Design, Development and Therapy as a formal scientific correspondence.
- 04Does not present new patient data or clinical trial results.
- 05Relevant to awareness of drug-induced tinnitus (medication-related ear ringing) in patients on mTOR inhibitors.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
The proposed causal chain linking everolimus to tinnitus is not adequately supported by the evidence presented in the original article.
opinionunclear✦ Research metadata ✦
- PMID
- 42903802
- DOI
- 10.2147/DDDT.S659416.
- Journal
- Drug Design, Development and Therapy
- Publication type
- editorial
- Evidence level
- 5
- Population
- Not applicable — letter critiquing a prior publication; no study population
- Intervention
- Everolimus (mTOR inhibitor) and its proposed association with tinnitus
Primary outcomes
Validity of the causal mechanism proposed to link everolimus use to tinnitus onset